Our discovery of AMPK-mediated regulation of HER2 and EGFR signaling provides a novel mechanism to explain heightened sensitivity of HER2 and EGFR overexpressing breast cancer cell lines to the AMPK activating agent, AICAR. Here, EGFR is linked to breast carcinoma.